In the cluster randomised VITAL-AF trial, screening patients during primary care visits using a single-lead ECG was feasible but not associated with a significant increase in new atrial fibrillation (AF) diagnoses compared with usual care . However, it may be useful in patients aged ≥85 years.
Dr Steven Lubitz (Massachusetts General Hospital, USA) said screening in primary care might be optimal because it can identify people who might benefit from treatment at a large scale and enable efficient treatment initiation. In VITAL-AF (NCT03515057), patients aged ≥65 years from 16 hospital- and community-based practices were randomised 1:1 to usual care or AF screening, using an AliveCor single-lead ECG, during routine visits. The primary endpoint was the rate of newly diagnosed AF over a period of 12 months. A total of 30,722 patients...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Fewer CV complications than expected in AHA COVID-19 Registry Next Article
Active screening for AF improves clinical outcomes »